-
ONCOL RES 2025 10.32604/or.2024.049054
Comprehensive molecular characterization to predict immunotherapy response in advanced biliary tract cancer: a phase II trial of pembrolizumab
Kim, R; Park, JK; Kwon, M; An, M; Hong, JY; Park, JO; Lim, SH; Kim, ST
View PubMed
-
J CACHEXIA SARCOPENI 2024 10.1002/jcsm.13643
Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer
Min, JH; Yu, JI; Kim, SH; Kim, YK; Kim, K; Park, HC; Park, JO; Hong, JY; Lee, KT; Lee, KH; Lee, JK; Park, JK; Choi, JH; Heo, JS; Han, IW; Kim, H; Shin, SH; Yoon, SJ; Woo, SY
View PubMed
-
EXP CELL RES 2024 10.1016/j.yexcr.2024.114248
Exosomal miR-155-5p drives ibrutinib resistance in B-cell lymphoma
Park, B; Choi, ME; Ryu, KJ; Park, C; Choi, M; Yoon, SE; Kim, WS; Kim, HH; Hong, JY; Kim, SJ
View PubMed
-
EUR J CANCER 2024 10.1016/j.ejca.2024.114312
Prediabetes persistence or remission and subsequent risk of gallbladder cancer: A nationwide cohort study
Park, JH; Hong, JY; Han, KYD; Park, YS; Park, JO; Lim, HY; Shen, JJ
View PubMed
-
CANCER-AM CANCER SOC 2024 10.1002/cncr.35609
Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-09)
Kim, M; Kim, YJ; Suh, KJ; Kim, SH; Kim, JE; Jeong, J; Hong, JY; Lee, J; Lee, SJ; Oh, SY; Kim, JH; Lee, GW; Ahn, MS; Choi, W; Choi, YJ; Lee, T; Oum, C; Kim, J; Kim, YS; Ahn, JH
View PubMed
-
PATHOL RES PRACT 2024 10.1016/j.prp.2024.155473
Prevalence of KRAS amplification in patients with metastatic cancer: Real-world next-generation sequencing analysis
Choi, DH; Jang, HL; Lim, SH; Kim, ST; Hong, JY; Park, SH; Park, JO; Kim, DG; Kim, KM; Lee, J
View PubMed
-
LIVER CANCER 2024 10.1159/000540969
Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries
Lee, CK; Yoo, C; Hong, JY; Park, SJ; Kim, JW; Tai, DWM; Kim, H; Korphaisarn, K; Tanasanvimon, S; Chen, SC; Kim, JW; Kim, I; Kim, M; Choo, J; Oh, SB; Chen, CT; Bae, WK; Kim, H; Huh, SJ; Yen, CJ; Park, S; Lee, DK; Chan, LL; Kang, BD; Kang, MS; Sundar, R; Choi, HJ; Chan, SL; Chon, HJ; Lee, MA
View PubMed
-
TRANSL CANCER RES 2024 10.21037/tcr-24-20
CDK4/6 inhibition to resensitize BRAF/EGFR inhibitor in patient-derived BRAF/PTEN-mutant colon cancer cells
Lim, SH; Lee, SY; Hong, JY; Lee, J; Kim, ST
View PubMed
-
CANCER LETT 2024 10.1016/j.canlet.2024.217041
The safety and efficacy outcomes of Minnelide given alone or in combination with paclitaxel in advanced gastric cancer: A phase I trial
Lim, SH; Saluja, A; Vickers, S; Hong, JY; Kim, ST; Lavania, S; Pandey, S; Gupta, VK; Velagapudi, MR; Lee, J
View PubMed
-
J CANCER RES THER 2024 10.4103/jcrt.jcrt_2698_22
Imatinib in c-KIT-mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18-05 Trial)
Kim, HR; Lee, SJ; Ahn, MS; Kim, JE; Kang, MJ; Hong, JY; Lee, J; Kim, ST
View PubMed
-
INT J CLIN ONCOL 2024 10.1007/s10147-024-02506-2
Favorable clinical efficacy of cytotoxic chemotherapy in patients with progressive desmoid tumors: a retrospective real-world study
Oh, CR; Jeong, H; Kim, W; Lee, JS; Song, SY; Song, JS; Cho, KJ; Chung, HW; Lee, MH; Hong, JY; Lee, J; Kim, JE; Ahn, JH
View PubMed
-
CLIN TRANSL RAD ONCO 2024 10.1016/j.ctro.2024.100732
Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy
Kim, K; Park, HC; Yu, JI; Park, JO; Hong, JY; Lee, KT; Lee, KH; Lee, JK; Park, JK; Heo, JS; Shin, SH; Min, JH; Kim, K; Han, IW
View PubMed
-
JHEP REP 2024 10.1016/j.jhepr.2023.100991
Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study
Kim, BH; Park, HC; Kim, TH; Koh, YH; Hong, JY; Cho, Y; Sinn, DH; Park, B; Park, JW
View PubMed
-
NAT MED 2024 10.1038/s41591-024-02824-y
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial
Kim, HD; Jung, S; Lim, HY; Ryoo, BY; Ryu, MH; Chuah, S; Chon, HJ; Kang, B; Hong, JY; Lee, HC; Moon, DB; Kim, KH; Kim, TW; Tai, D; Chew, V; Lee, JS; Finn, RS; Koh, JY; Yoo, C
View PubMed
-
BIOMATERIALS 2024 10.1016/j.biomaterials.2024.122504
Patient-derived tumor spheroid-induced angiogenesis preclinical platform for exploring therapeutic vulnerabilities in cancer
Ko, JH; Hyung, S; Heo, YJ; Jung, SM; Kim, ST; Park, SH; Hong, JY; Lim, SH; Kim, KM; Yoo, S; Li Jeon, N; Lee, JY
View PubMed
-
CANCERS 2023 10.3390/cancers15245745
Adverse Effect of the Duration of Antibiotic Use Prior to Immune Checkpoint Inhibitors on the Overall Survival of Patients with Recurrent Gynecologic Malignancies
Jung, HJ; Park, JH; Oh, J; Lee, SM; Jang, I; Hong, JY; Lee, YY; Choi, HJ
View PubMed
-
BIOMEDICINES 2023 10.3390/biomedicines11123264
Prevalence of RAF1 Aberrations in Metastatic Cancer Patients: Real-World Data
Lim, SH; Jung, J; Hong, JY; Kim, ST; Park, SH; Park, JO; Kim, KM; Lee, J
View PubMed
-
J NATL COMPR CANC NE 2023 10.6004/jnccn.2023.7060
Smoking Cessation and Pancreatic Cancer Risk in Individuals With Prediabetes and Diabetes: A Nationwide Cohort Study
Park, JH; Hong, JY; Shen, JJ; Han, K; Park, YS; Park, JO
View PubMed
-
ANTICANCER RES 2023 10.21873/anticanres.16607
Pemetrexed and Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer Who Failed Gemcitabine-containing Chemotherapy: A Phase II Single-arm Prospective Study
Lim, SH; Hong, JY; Park, JO; Park, YS; Kim, ST
View PubMed
-
CANCERS 2023 10.3390/cancers15153841
A Machine Learning Approach Using FDG PET-Based Radiomics for Prediction of Tumor Mutational Burden and Prognosis in Stage IV Colorectal Cancer
Lee, H; Moon, SH; Hong, JY; Lee, J; Hyun, SH
View PubMed
-
JCO PRECIS ONCOL 2023 10.1200/PO.22.00537
Clinical Implication of HER2 Aberration in Patients With Metastatic Cancer Using Next-Generation Sequencing: A Pan-Tumor Analysis
Jung, J; Kim, ST; Ko, J; Hong, JY; Park, JO; Ha, SY; Lee, J
View PubMed
-
J CLIN ONCOL 2023 10.1200/JCO.22.01740
Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study
Park, JH; Hong, JY; Shen, JJ; Han, K; Park, JO; Park, YS; Lim, HY
View PubMed
-
CANCER MED-US 2023 10.1002/cam4.6190
Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG-RC20-06
Sohn, BS; Kim, J; Kim, M; Hong, JY; Lee, J; Park, SE; Kim, H; Lee, HJ; Kang, EJ; Lee, SI; Lee, IH; Huh, SJ; Jo, J; Kim, HY
View PubMed
-
THER ADV GASTROENTER 2023 10.1177/17562848231170484
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation
Jeong, SY; Hong, JY; Park, JO; Park, YS; Lim, HY; Jang, JY; Jeon, Y; Kim, ST
View PubMed
-
CLIN MOL HEPATOL 2023 10.3350/cmh.2022.0404
Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective
Goh, MJ; Sinn, DH; Kim, JM; Lee, MW; Hyun, DH; Il Yu, J; Hong, JY; Choi, MS
View PubMed
-
CANCER RES TREAT 2023 10.4143/crt.2022.251
Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response
Hong, JY; Cho, HJ; Yun, KH; Lee, YH; Kim, SH; Baek, W; Kim, SK; Lee, Y; Choi, YL; Kwon, M; Kim, HS; Lee, J
View PubMed
-
CANCER RES TREAT 2023 10.4143/crt.2022.343
Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
Kim, H; Jeong, BC; Hong, J; Kwon, GY; Kim, CK; Park, W; Pyo, H; Song, W; Sung, HH; Hong, JY; Park, SH
View PubMed
-
LIVER CANCER 2023 10.1159/000529609
Association Between Smoking Cessation and the Risk of Cholangiocarcinoma and Ampulla of Vater Cancer: A Nationwide Cohort Study
Park, JH; Hong, JY; Han, KD
View PubMed
-
DIABETES CARE 2023 10.2337/dc22-0961
Association Between Glycemic Status and the Risk of Kidney Cancer in Men and Women: A Nationwide Cohort Study
Park, JH; Hong, JY; Han, K; Shen, JJ
View PubMed
-
CANCER MED-US 2023 10.1002/cam4.5530
Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancers
Kim, JE; Kim, H; Kim, B; Chung, HG; Chung, HH; Kim, KM; Kim, SH; Jeong, WK; Kim, YK; Min, JH; Heo, JS; Han, IW; Shin, SH; Park, HC; Yu, JI; Park, JO; Kim, ST; Hong, JY; Lee, SH; Lee, KH; Lee, JK; Lee, KT; Jang, KT; Park, JK
View PubMed
-
EUR J CANCER 2022 10.1016/j.ejca.2022.11.031
Threshold dose-response association between smoking pack-years and the risk of gallbladder cancer: A nationwide cohort study
Park, JH; Hong, JY; Han, K
View PubMed
-
J CLIN ONCOL 2022 10.1200/JCO.22.00145
Light-to-Moderate Alcohol Consumption Increases the Risk of Biliary Tract Cancer in Prediabetes and Diabetes, but Not in Normoglycemic Status: A Nationwide Cohort Study
Park, JH; Hong, JY; Han, K; Park, YS; Park, JO
View PubMed
-
PATHOL ONCOL RES 2022 10.3389/pore.2022.1610697
MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer
Ko, J; Jung, J; Kim, ST; Hong, JY; Park, S; Park, JO; Park, YS; Lim, HY; Ahn, S; Kim, KM; Kang, WK; Lee, J
View PubMed
-
CLIN ONCOL-UK 2022 10.1016/j.clon.2022.02.011
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer
Jo, H; Lee, MS; Lee, YP; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
View PubMed
-
J IMMUNOTHER CANCER 2022 10.1136/jitc-2022-005041
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer
Kwon, M; Kim, G; Kim, R; Kim, KT; Kim, ST; Smith, S; Mortimer, PGS; Hong, JY; Loembe, AB; Irurzun-Arana, I; Koulai, L; Kim, KM; Kang, WK; Dean, E; Park, WY; Lee, J
View PubMed
-
CANCER RES TREAT 2022 10.4143/crt.2021.854
Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy
Kim, R; Hong, JY; Lee, J; Kwon, GY; Jeong, BC; Park, SH
View PubMed
-
THER ADV MED ONCOL 2022 10.1177/17588359221113266
The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma
Kim, HS; Kim, CG; Hong, JY; Kim, IH; Kang, B; Jung, S; Kim, C; Shin, SJ; Choi, HJ; Cheon, J; Chon, HJ; Lim, HY
View PubMed
-
BIOMEDICINES 2022 10.3390/biomedicines10071565
Clinical Significance of Preoperative Hematological Parameters in Patients with D2-Resected, Node-Positive Stomach Cancer
Park, JS; Yu, JI; Lim, DH; Nam, H; Kim, YI; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM
View PubMed
-
SCI REP-UK 2022 10.1038/s41598-022-14856-w
Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease
Park, JH; Hong, JY; Han, K; Kang, W; Park, JK
View PubMed
-
FRONT ONCOL 2022 10.3389/fonc.2022.888755
Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis
Yu, JI; Kang, W; Yoo, GS; Goh, MJ; Sinn, DH; Gwak, GY; Paik, YH; Choi, MS; Lee, JH; Koh, KC; Paik, SW; Hong, JY; Lim, HY; Park, B; Park, HC
View PubMed
-
ANN SURG ONCOL 2022 10.1245/s10434-022-11688-w
ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer
Yu, JI; Yoo, GS; Park, HC; Choi, DH; Lee, WY; Yun, SH; Kim, HC; Cho, YB; Huh, JW; Park, YA; Shin, JK; Park, JO; Kim, ST; Park, YS; Lee, J; Kang, WK; Lim, HY; Hong, JY
View PubMed
-
ANN SURG ONCOL 2022 10.1245/s10434-022-11592-3
Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer
Yu, JI; Yoo, GS; Park, HC; Choi, DH; Lee, WY; Yun, SH; Kim, HC; Cho, YB; Huh, JW; Park, YA; Shin, JK; Park, JO; Kim, ST; Park, YS; Lee, J; Kang, WK; Lim, HY; Hong, JY
View PubMed
-
J ONCOL 2022 10.1155/2022/9714570
Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
Hyung, S; Han, B; Jung, J; Kim, ST; Hong, JY; Park, SH; Zang, DY; Park, JO; Park, YS; Kim, KM; Kang, WK; Lee, J
View PubMed
-
J CANCER 2022 10.7150/jca.67050
Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm phase-II trial
Kim, R; Ji, JH; Kim, JH; Hong, JY; Lim, HY; Kang, WK; Lee, J; Kim, ST
View PubMed
-
GASTROENTEROLOGY 2022 10.1053/j.gastro.2021.09.070
Changes in Metabolic Syndrome Status are Associated With Altered Risk of Pancreatic Cancer: A Nationwide Cohort Study
Park, JH; Han, K; Hong, JY; Park, YS; Hur, KY; Kang, G; Park, JO
View PubMed
-
EUR J CANCER 2022 10.1016/j.ejca.2021.12.027
Association between alcohol consumption and pancreatic cancer risk differs by glycaemic status: A nationwide cohort study
Park, JH; Han, K; Hong, JY; Park, YS; Park, JO
View PubMed
-
GENOME MED 2022 10.1186/s13073-021-00995-8
Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial
Hong, JY; Cho, HJ; Sa, JK; Liu, XQ; Ha, SY; Lee, T; Kim, H; Kang, W; Sinn, DH; Gwak, GY; Choi, MS; Lee, JH; Koh, KC; Paik, SW; Park, HC; Kang, TW; Rhim, H; Lee, SJ; Cristescu, R; Lee, J; Paik, YH; Lim, HY
View PubMed
-
BRIT J RADIOL 2021 10.1259/bjr.20210352 2021
Long-term follow-up of oxaliplatin-induced liver damage in patients with colorectal cancer
Cha1, DI; Song, KD; Ha, SY; Hong, JY; Hwang, JA; Ko, SE
View PubMed
-
EUR J CANCER 2021 10.1016/j.ejca.2021.03.024 2021
Association between non-alcoholic fatty liver disease and the risk of biliary tract cancers: A South Korean nationwide cohort study
Park1, JH; Hong, JY; Kwon, M; Lee, J; Han, K; Han, IW; Kang, W; Park, JK
View PubMed
-
EUR RADIOL 2021 10.1007/s00330-021-08094-3 2021
Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer
Cha1, DI; Lee, J; Jeong, WK; Kim, ST; Kim, JH; Hong, JY; Kang, WK; Kim, KM; Kim, SW; Choi, D
View PubMed
-
CANCER MANAG RES 2021 10.2147/CMAR.S309092 2021
Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
Lee1, YP; Hong, JY; Yoon, SE; Cho, J; Shim, JH; Bang, Y; Kim, WS; Kim, SJ
View PubMed
-
ESMO OPEN 2021 10.1016/j.esmoop.2021.100049 2021
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
Park1, HS; Kang, B; Chon, HJ; Im, HS; Lee, CK; Kim, I; Kang, MJ; Hwang, JE; Bae, WK; Cheon, J; Park, JO; Hong, JY; Kang, JH; Kim, JH; Lim, SH; Kim, JW; Kim, JW; Yoo, C; Choi, HJ
View PubMed
-
ONCOLOGY-BASEL 2021 10.1159/000514404 2021
Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer
Kim1, H; Kim, J; Byeon, S; Jang, KT; Hong, JY; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
View PubMed
-
ANN ONCOL 2021 10.1016/j.annonc.2020.11.017 2021
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial
Park1, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK
View PubMed
-
THER ADV MED ONCOL 2021 10.1177/1758835921992992 2021
Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors
Kim1, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
View PubMed
-
CANCERS 2021 10.3390/cancers13010059 2021
Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses
Park1, JS; Il Yu, J; Lim, D; Nam, H; Kim, YI; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM
View PubMed
-
GENOME MED 2021 10.1186/s13073-021-00826-w 2021
Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial
Kim1, ST; Sa, JK; Oh, SY; Kim, K; Hong, JY; Kang, WK; Kim, KM; Lee, J
View PubMed
-
IN VIVO 2021 10.21873/invivo.12284 2021
ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy
Kim1, H; Kim, ST; Yoo, KH; Hong, JY; Park, YS; Lim, HY; Park, JO
View PubMed
-
J CANCER 2021 10.7150/jca.49176 2021
Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer
Kim1, J; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
View PubMed
-
LIVER INT 2021 10.1111/liv.15102
Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma
Cheon, J; Yoo, C; Hong, JY; Kim, HS; Lee, DW; Lee, MA; Kim, JW; Kim, I; Oh, SB; Hwang, JE; Chon, HJ; Lim, HY
View PubMed
-
J CANCER RES CLIN 2021 10.1007/s00432-021-03781-6
The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
Kim, H; Ahn, S; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
View PubMed
-
CLIN CANCER RES 2021 10.1158/1078-0432.CCR-21-0251
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
Kim, ST; Smith, SA; Mortimer, P; Loembe, AB; Cho, H; Kim, KM; Smith, C; Willis, S; Irurzun-Arana, I; Berges, A; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kozarewa, I; Pierce, AJ; Dean, E; Lee, J
View PubMed
-
CANCER MED-US 2021 10.1002/cam4.4259
Reducing tumor invasiveness by ramucirumab and TGF-beta receptor kinase inhibitor in a diffuse-type gastric cancer patient-derived cell model
Lee, SY; Byeon, S; Ko, J; Hyung, S; Lee, IK; Li Jeon, N; Hong, JY; Kim, ST; Park, SH; Lee, J
View PubMed
-
CANCER DISCOV 2021 10.1158/2159-8290.CD-21-0219
Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer
Kwon, M; An, M; Klempner, SJ; Lee, H; Kim, KM; Sa, JK; Cho, HJ; Hong, JY; Lee, TY; Min, YW; Kim, TJ; Min, BH; Park, WY; Kang, WK; Kim, KT; Kim, ST; Lee, J
View PubMed
-
THER ADV MED ONCOL 2021 10.1177/17588359211038478
Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer
Hong, JY; Cho, HJ; Kim, ST; Park, YS; Shin, SH; Han, IW; Lee, JY; Heo, JS; Park, JO
View PubMed
-
EUR J CANCER 2021 10.1016/j.ejca.2021.06.052
Persistent status of metabolic syndrome and risk of cholangiocarcinoma: A Korean nationwide population- based cohort study
Park, JH; Hong, JY; Park, YS; Kang, GS; Han, K; Park, JO
View PubMed
-
METABOLISM 2021 10.1016/j.metabol.2021.154848
Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk: A nationwide cohort study
Park, JH; Hong, JY; Park, YS; Kang, G; Han, K; Park, JO
View PubMed
-
J CANCER 2021 10.7150/jca.62853
When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer
Kim, H; Kim, H; Lee, M; Kwon, M; Hong, JY; Lee, J; Lim, HY; Kang, WK; Kim, ST
View PubMed
-
FRONT IMMUNOL 2021 10.3389/fimmu.2021.701668
Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody
Kim, N; Yu, JI; Lim, DH; Lee, J; Kim, ST; Hong, JY; Kang, WK; Jeong, WK; Kim, KM
View PubMed
-
THER ADV MED ONCOL 2020 10.1177/1758835920965842 2020
Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment
Lee1, MS; Cho, HJ; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Cho, YB; Kim, ST
View PubMed
-
CANCER IMMUNOL IMMUN 2020 10.1007/s00262-020-02794-3 2020
Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab
Kim1, N; Yu, JI; Park, HC; Yoo, GS; Choi, C; Hong, JY; Lim, HY; Lee, J; Choi, MS; Lee, JE; Kim, K
View PubMed
-
RADIOTHER ONCOL 2020 10.1016/j.radonc.2020.07.043 2020
Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer Analysis of the ARTIST phase III trial
Yu1, JI; Choi, C; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Nam, H; Lim, DH
View PubMed
-
CANCER EPIDEM BIOMAR 2020 10.1158/1055-9965.EPI-20-0594 2020
Obesity Has a Stronger Relationship with Colorectal Cancer in Postmenopausal Women than Premenopausal Women
Chang1, JW; Shin, DW; Do Han, K; Jeon, KH; Yoo, JE; Cho, IY; Choi, YJ; Hong, JY
View PubMed
-
GASTRIC CANCER 2020 10.1007/s10120-020-01124-x 2020
Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors
Kim1, YY; Lee, J; Jeong, WK; Kim, ST; Kim, JH; Hong, JY; Kang, WK; Kim, KM; Sohn, I; Choi, D
View PubMed
-
ANN SURG ONCOL 2020 10.1245/s10434-020-08408-7 2020
Regional Lymph Node Metastasis of Scalp Angiosarcoma A Detailed Clinical Observation Study of 40 Cases
Kang1, Y; Bae, J; Choi, S; Jang, KT; Yu, J; Hong, JY; Lim, SY; Jeong, HS
View PubMed
-
TARGET ONCOL 2020 10.1007/s11523-020-00731-z 2020
Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma A Multicenter Retrospective Cohort Study
Oh1, CR; Hong, JY; Kim, JH; Lee, JS; Kim, HS; Kim, TW; Ahn, JH; Kim, JE
View PubMed
-
THER ADV MED ONCOL 2020 10.1177/1758835920926796 2020
First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients
Kim1, ST; Hong, JY; Park, SH; Park, JO; Park, YW; Park, N; Lee, H; Hong, SH; Lee, SJ; Song, SW; Kim, K; Park, YS; Lim, HY; Kang, WK; Nam, H; Lee, JW; Park, K; Kim, KM; Lee, J
View PubMed
-
LIVER INT 2020 10.1111/liv.14496 2020
Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events
Yoo1, C; Byeon, S; Bang, Y; Cheon, J; Kim, JW; Kim, JH; Chon, HJ; Kang, B; Kang, MJ; Kim, I; Hwang, JE; Kang, JH; Lee, MA; Hong, JY; Lim, HY; Ryoo, BY
View PubMed
-
Transl Cancer Res 2020 10.21037/tcr-19-1876 2020
Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
Hong1, JY; An, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, KM; Kang, WK; Kim, ST
View PubMed
-
TARGET ONCOL 2020 10.1007/s11523-020-00713-1 2020
Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients
Kim1, J; Byeon, S; Kim, H; Yeo, JH; Hong, JY; Lee, J; Lim, HY; Kang, WK; Kim, ST
View PubMed
-
TARGET ONCOL 2020 10.1007/s11523-020-00706-0 2020
Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study
Byeon1, S; Hong, JY; Lee, J; Nam, DH; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
View PubMed
-
PATHOL RES PRACT 2020 10.1016/j.prp.2020.152820 2020
TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer
Hong1, JY; Kim, HJ; Kim, K; Hong, J; Kim, JE; Byeon, SJ; Lee, IK; Kim, KM; Shim, M; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, J; Kang, WK
View PubMed
-
ESMO OPEN 2020 10.1136/esmoopen-2020-000670 2020
Clinical scoring system for the prediction of survival of patients with advanced gastric cancer
Kim1, J; Hong, JY; Kim, ST; Park, SH; Jekal, SY; Choi, JS; Chang, DK; Kang, WK; Seo, SW; Lee, J
View PubMed
-
Genome Med 2020 10.1186/s13073-020-0717-8 2020
Comprehensive pharmacogenomic characterization of gastric cancer
Sa1, JK; Hong, JY; Lee, IK; Kim, JS; Sim, MH; Kim, HJ; An, JY; Sohn, TS; Lee, JH; Bae, JM; Kim, S; Kim, KM; Kim, ST; Park, SH; Park, JO; Lim, HY; Kang, WK; Her, NG; Lee, Y; Cho, HJ; Shin, YJ; Kim, M; Koo, H; Kim, M; Seo, YJ; Kim, JY; Choi, MG; Nam, DH; Lee, J
View PubMed
-
TARGET ONCOL 2020 10.1007/s11523-019-00691-z 2020
Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study
Kim1, ST; Hong, JY; Lee, JY; Park, JO; Lim, HY; Kang, WK; Park, YS
View PubMed
-
LEUKEMIA LYMPHOMA 2020 10.1080/10428194.2019.1709831 2020
Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP
Kang1, J; Chae, H; Hong, JY; Yoon, DH; Kim, S; Park, JS; Lee, SW; Park, CS; Ryu, JS; Huh, J; Suh, C
View PubMed
-
J ONCOL 2020 10.1155/2020/4659062 2020
Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers
Lee1, SJ; Hong, JY; Kim, K; Kim, KM; Kang, SY; Lee, T; Kim, ST; Park, SH; Park, YS; Lim, HY; Kang, WK; Lee, J; Park, JO
View PubMed
-
CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442 2019
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial
Lee1, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK
View PubMed
-
PLoS One 2019 10.1371/journal.pone.0215080 2019
Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system
Cho1, JH; Kim, JS; Kim, ST; Hong, JY; Park, JO; Park, YS; Nam, DH; Lee, DW; Lee, J
View PubMed
